Financial PositionMesoblast is funded well into 2026, potentially extending further depending on the launch trajectory of Ryoncil in pediatric steroid refractory acute graft vs. host disease.
Market OpportunityThe potential pricing for Ryoncil in excess of $1.5M for a full course supports a significant market opportunity, validating the view that the GvHD opportunity alone could support Mesoblast's current valuation.
Regulatory ApprovalThe FDA supports an accelerated approval pathway for Revascor after appraising the totality of data, including significant improvements on endpoints like mortality.